<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00148317</url>
  </required_header>
  <id_info>
    <org_study_id>0504007841</org_study_id>
    <nct_id>NCT00148317</nct_id>
  </id_info>
  <brief_title>Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma</brief_title>
  <official_title>A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <brief_summary>
    <textblock>
      PRIMARY STUDY OBJECTIVES

        -  To evaluate the efficacy of the combination of bortezomib, dexamethasone, with and
           without DOXIL, followed by high-dose cyclophosphamide as a therapy for two different
           subsets of multiple myeloma patients:

             1. Patients post first line therapy

             2. Patients with relapsed/refractory disease who are bortezomib-naïve

        -  To evaluate the safety of the combination of bortezomib and dexamethasone, with and
           without DOXIL, followed by high-dose cyclophosphamide as therapy for patients with
           multiple myeloma.

      SECONDARY STUDY OBJECTIVES

        -  To evaluate the role of the combination of bortezomib dexamethasone, with and without
           DOXIL, followed by high-dose cyclophosphamide on the ability to collect &gt; 10 x 106 CD34+
           cells/kg in &lt; 7 collections (for both subsets of multiple myeloma patients).

        -  To evaluate the survival of patients who receive the combination of bortezomib
           dexamethasone, with and without DOXIL, followed by high-dose cyclophosphamide (for both
           subsets of patients).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Consolidation: All patients will receive 2 cycles of bortezomib (VEL) and dexamethasone (DEX). Patients who achieve a complete response after 2 cycles will receive 4 additional cycles of VEL/DEX before mobilization.
Patients who do not achieve at least a partial response after 2 cycles will receive 4 more cycles of VEL/DEX plus DOXIL.
Patients who achieve a partial response after 2 cycles on VEL/DEX, will continue this combination for 2 more cycles. Patients who achieve a complete response after 4 cycles will receive 2 additional cycles of VEL/DEX before mobilization. Patients who remain with a partial response after 4 cycles of VEL/DEX will receive 2 additional cycles of the combination of VEL/DEX plus DOXIL.
Mobilization: Patients who complete 6 cycles of consolidation will proceed to mobilization. Patients will receive one cycle of VEL plus high dose CYTOXAN followed by G-CSF beginning 24 hours after CYTOXAN given for a total of 10 daily doses.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate)</measure>
    <time_frame>Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization</time_frame>
    <description>Myeloma response criteria developed by Bladé et al. was used to categorize response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yield of CD34+ Stem Cells</measure>
    <time_frame>Occurred after mobilization, and prior to Stem cell transplant; a 7 day limit was imposed on stem cell collection</time_frame>
    <description>This is the yield of CD34+ stem cells collection after high dose cyclophosphamide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Date of progression, assessed from start of trial to Final data cut off date (15 April 2011)</time_frame>
    <description>Response was assessed using IMWG guidelines, which for progressive disease are as follows:
Increase of &gt; 25% from lowest response value in any one or more of the following:
Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL)*
Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h)
Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be &gt; 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must be &gt; 10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder IF starting M protein component is &gt; 5g/dL, then absolute increase of 1g is sufficient for progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin</intervention_name>
    <description>If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophoshamide</intervention_name>
    <description>During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must voluntarily sign and understand written informed consent.

          -  Confirmed diagnosis of multiple myeloma as specified by the SWOG criteria and is
             detailed in Appendix I.

          -  Measurable disease as defined the following:

               1. For patients post induction therapy, any measurable paraprotein in the serum or
                  urine and/or any plasmacytoma present on physical exam or imaging.

               2. For patients with relapsed/refractory disease, &gt; 0.5 g/dL serum monoclonal
                  protein, &gt; 0.1 g/dL serum free light chains, &gt; 0.2 g/24 hrs urinary M-protein
                  excretion, and/or measurable plasmacytoma(s).

          -  Age &gt; or = than 18 years at the time of signing the informed consent form.

          -  Karnofsky performance status&gt; or =70% (&gt;60% if due to bony involvement of myeloma).

          -  Group A (post-induction therapy)- patients who have received only one prior treatment
             regimen (eg VAD, Thal/Dex, BLT-D, MP, BiRD, or DVd) with at least 20 patients having
             received a Revlimid based regimen or Group B(&gt;1st line of therapy)- patients with
             relapsed/refractory multiple myeloma who have received two or more prior treatment
             regimens .

          -  If the patient is a woman of childbearing age, she must have a negative serum or urine
             pregnancy test within 7 days of starting study and must use effective contraception
             throughout the course of the study.

          -  Life expectancy &gt; 12 weeks.

          -  Absolute neutrophil count (ANC)&gt; or = 1500 cells/mm3 (&gt; or = 1000 for patients with
             bone marrow biopsy displaying &gt; 50% involvement by myeloma)

          -  Platelets count &gt; or = 50,000/mm3 (&gt; or = 30,000 for patients with bone marrow biopsy
             displaying &gt; 50% involvement by myeloma)

          -  Hemoglobin &gt; 9.0 g/dL

          -  Serum SGOT/AST &lt;3.0 x upper limits of normal (ULN)

          -  Serum SGPT/ALT &lt;3.0 x upper limits of normal (ULN)

          -  Serum creatinine &lt; 2.5 mg/dL or creatinine clearance &gt; 40ml/min

          -  Serum total bilirubin &lt; 1.5 x ULN

          -  Patients must have a MUGA scan with LVEF &gt;50%

        Exclusion Criteria:

          -  Patients with non-secretory MM (no measurable monoclonal protein, free light chains,
             and/or M-spike in blood or urine) unless measurable disease is available with imaging
             techniques such as MRI and PET scan.

          -  Prior treatment with bortezomib.

          -  Peripheral neuropathy of &gt; Grade 2 as defined by CTCAE Version 3.0 (see Appendix II)

          -  History of allergic reactions to compounds containing mannitol, bortezomib,
             conventional formulation of doxorubicin HCL or the components of DOXIL.

          -  Prior history of other malignancies (except for basal cell or squamous cell carcinoma
             of the skin or carcinoma in situ of the cervix or breast) unless disease free for ³ 5
             years.

          -  NYHA Class III or IV heart disease. History of active unstable angina, congestive
             heart disease, serious uncontrolled cardiac arrhythmia or myocardial infarction within
             6 months.

          -  Female patients who are pregnant or breastfeeding. Women of childbearing potential and
             men must agree to use adequate contraception prior to study entry and for the duration
             of study participation.

          -  Known HIV or hepatitis A, B, or C positivity

          -  Active viral or bacterial infections or any coexisting medical problem that would
             significantly increase the risks of this treatment program.

          -  Any concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric
             illness which could place him/her at unacceptable risk, including, but not limited to,
             uncontrolled hypertension, uncontrolled diabetes, active uncontrolled infection,
             and/or acute chronic liver disease (i.e., hepatitis, cirrhosis).

          -  No prior anti-myeloma therapy within 2 weeks of treatment initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Niesvizky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.med.cornell.edu/cancercare/trials/</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>February 24, 2017</results_first_submitted>
  <results_first_submitted_qc>June 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2017</results_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Consolidation (VEL + DEX)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DOXIL Added at Cycle 3</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>DOXIL Added at Cycle 5</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>no DOXIL Added</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Mobilization (VEL+CYTOXAN+FILGRASTIM)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unable to tolerate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm (All Patients)</title>
          <description>Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide: Bortezomib 1.3 mg/m2 days 1, 4, 8, 11 (initial cycles) Dexamethasone 40 mg Days 1-4, 8-11, 15-18 (initial cycles) Doxil 30 mg/m2 Day 4 of subsequent cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="27" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age &lt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &gt; or = 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta-2 Microglubilin</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.05" lower_limit="1.0" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Albumin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="2.0" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Durie Salmon Staging System</title>
          <description>The Durie Salmon Staging System was used to assess patients status. Stage 1A is associated with a better outcome &amp; a low tumor burden, stage 2A with a intermediate outcome and tumor burden, and stage 3A with a worse outcome &amp; higher tumor burden. Criteria for staging is based on multiple factors including hematology values, disease burden, and renal function. The staging system can be found here: https://www.themmrf.org/multiple-myeloma/prognosis/myeloma-stages/durie-salmon-staging-system/ As assessed by the treating physician, the 1a subject:had active myeloma based on the IMWG criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Staging System</title>
          <description>Measure Description: Stage I ß2-M &lt; 3.5 mg/dL and albumin =3.5 g/dL Stage II Neither stage I nor stage III Stage III ß2-M ≥ 5.5 mg/L</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Abnormalities by FISH</title>
          <description>Cytogenetic abnormalities were assessed in patients using fluorescence in situ hybridization (FISH), which detects chromosomal abnormalities. Del (17p), t(4;14), and t (14;16) were considered High Risk cytogenetic abnormalities. All other abnormalities were considered standard risk cytogenetics.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>trisomy 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hyperdiploidy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t (4;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>del (17p)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t (11;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t (14;16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior induction therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>lenalidomide + dexamethasone ± BIAXIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thalidomide + lenalidomide + dexamethasone± BIAXIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thalidomide + dexamethasone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>thalidomide only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pulsed dexamethasone only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>melphalan + cyclophosphamide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dexamethasone, then single-agent lenalidomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best response prior to induction therapy</title>
          <description>Best response was noted using the International Myeloma Working Group Guidelines: http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate)</title>
        <description>Myeloma response criteria developed by Bladé et al. was used to categorize response.</description>
        <time_frame>Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization</time_frame>
        <population>All 38 patients were treated with DoVeD consolidation therapy (Vel + DEX with or without DOXIL). Of the 38 patients enrolled, 27 proceeded to mobilization (11 did not undergo mobilization). Responses were assessed prior to mobilization (post DoVED), and again after mobilization, to see if mobilization improved patient response.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - Post Mobilization</title>
            <description>This is the response rate assessed for patients after their bortezomib-based mobilization.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Arm - Responses Prior to Mobilization</title>
            <description>This is the overall best response rate (ORR, ≥PR, as measured by ≥50% reduction in M-protein) to DoVeD therapy from post-primary induction (pre-DoVeD).</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate)</title>
          <description>Myeloma response criteria developed by Bladé et al. was used to categorize response.</description>
          <population>All 38 patients were treated with DoVeD consolidation therapy (Vel + DEX with or without DOXIL). Of the 38 patients enrolled, 27 proceeded to mobilization (11 did not undergo mobilization). Responses were assessed prior to mobilization (post DoVED), and again after mobilization, to see if mobilization improved patient response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stringent Complete Response (sCR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good Partial response (VGPR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Response (progression, stable disease, etc)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yield of CD34+ Stem Cells</title>
        <description>This is the yield of CD34+ stem cells collection after high dose cyclophosphamide.</description>
        <time_frame>Occurred after mobilization, and prior to Stem cell transplant; a 7 day limit was imposed on stem cell collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm - Post Bortezomib-based Mobilization</title>
            <description>Yield of stem cell collection for the group that underwent bortezomib-based Mobilization</description>
          </group>
        </group_list>
        <measure>
          <title>Yield of CD34+ Stem Cells</title>
          <description>This is the yield of CD34+ stem cells collection after high dose cyclophosphamide.</description>
          <units>10^6 cells/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="6.8" upper_limit="294.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Response was assessed using IMWG guidelines, which for progressive disease are as follows:
Increase of &gt; 25% from lowest response value in any one or more of the following:
Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL)*
Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h)
Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be &gt; 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must be &gt; 10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder IF starting M protein component is &gt; 5g/dL, then absolute increase of 1g is sufficient for progression.</description>
        <time_frame>Date of progression, assessed from start of trial to Final data cut off date (15 April 2011)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm (All Patients)</title>
            <description>Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide: Bortezomib 1.3 mg/m2 days 1, 4, 8, 11 (initial cycles) Dexamethasone 40 mg Days 1-4, 8-11, 15-18 (initial cycles) Doxil 30 mg/m2 Day 4 of subsequent cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Response was assessed using IMWG guidelines, which for progressive disease are as follows:
Increase of &gt; 25% from lowest response value in any one or more of the following:
Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dL)*
Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h)
Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels. The absolute increase must be &gt; 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must be &gt; 10%
Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcaemia (corrected serum calcium &gt; 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder IF starting M protein component is &gt; 5g/dL, then absolute increase of 1g is sufficient for progression.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" lower_limit="6.4" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety was monitored throughout the study, from start of study until when patients were removed (for either progression, toxicity, or to get a HD-SCT, which occurred up to 1 year after start of treatment).</time_frame>
      <desc>Safety was monitored throughout the study and adverse events (AEs) were graded by NCI-CTCAE version 3.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm (All Patients)</title>
          <description>Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide: Bortezomib 1.3 mg/m2 days 1, 4, 8, 11 (initial cycles) Dexamethasone 40 mg Days 1-4, 8-11, 15-18 (initial cycles) Doxil 30 mg/m2 Day 4 of subsequent cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>afebrile neutropenia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>hearing impariment</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>increased appetite</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myopathy</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>cramping</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral neuropathy (sensory)</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy (sensory)</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>hand and foot syndrome</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>nervousness</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <description>DOVED consolidation phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>mobilization phase</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Hess</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>6469629440</phone>
      <email>jmh2004@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

